Symptomatic treatment of Multiple Sclerosis (MS) is crucial, since it helps to lessen the
limitations that affect patients' daily lives. Tremors are a significant and frequent symptom in …

BACKGROUND: Intrathecal Baclofen is available to treat severe generalized spasticity in
Multiple Sclerosis (MS) unresponsive to oral drug delivery. OBJECTIVE: The aims of this …

Objectives Spasticity is associated with various neurological conditions. In this study the
authors analyzed the long term effects of intrathecal baclofen therapy in multiple sclerosis …

OBJECTIVE Multiple sclerosis (MS) is a chronic autoimmune disease that causes
demyelination and axonal loss. Walking difficulties are a common and debilitating symptom …

Background Spasticity is a frequent and disabling symptom in people with Multiple Sclerosis
(MS). Intrathecal baclofen (ITB) is an effective but infrequently used treatment in ambulant …

BACKGROUND: Spasticity is a frequent disabling symptom in patients with multiple
sclerosis, which contributes to functional deterioration. OBJECTIVE: To evaluate the long …

The majority of patients with multiple sclerosis (MS) have symptoms of spasticity that
increasingly impair function as the disease progresses. With appropriate treatment …

Intrathecal baclofen (ITB) is a recognized therapy for severe spasticity of both spinal and
cerebral origin, with documented positive clinical outcomes for many patients with multiple …

We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients
presenting severe spasticity, who had received intrathecal (IT) baclofen test injections …

Objective Evaluate long-term efficacy and safety of ITB in treating MS-related spasticity
over∼ 20 years of service provision in a single centre. Methods A single centre prospective …